The objective of this study was to compare the binding of cyclosporine to blood proteins between four healthy subjects and flYe liver and eight renal transplant patients. Fresh heparinized blood was obtained, to which suffIcient quantities of tritium-labelled cyclosporine and unlabelled cyc1osporine were added to blood samples or red blood cell (RBC) suspensions. Concentrations of cyc1osporine in whole blood, plasma, RBC suspension, and phosphate buffer were estimated by liquid scintigraphy. The blood:plasma ratio of CYc1osporine in transplant patients was significantly lower (P < .05) than that in healthy volunteers. The RBC:buffer ratio, a measure of affinity of RBCs for cyc1osporine, was highest in those with liver transplants and lowest in those with kidney transplants. The unbound fraction of cyclosporine in plasma was less in transplant patients than in healthy volunteers. The results of this study indicate that there are differences in blood protein binding of cyc1osporine between transplant patients that may contribute to the differences in the pharmacokinetics and pharmacodynamics of this drug. P lasma protein binding is an important determinant of drug disposition. The binding of drugs to plasma proteins is influenced by a variety of factors. 1 The effect of changes in protein binding on drug kinetics and drug activity depends on the kinetic property and the therapeutic index of the drug. Cyclosporine exhibits marked variability in its kinetics between patients. 2 It is known to be highly bound to plasma proteins in healthy subjects. 3 • 4 The objective of our study was to compare the binding of cyclosporine to blood proteins between healthy subjects and liver and renal transplant patients.
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PATIENTS AND METHODS
Fresh heparinized blood was obtained from eight kidney transplant patients, fIve liver transplant patients, and four healthy volunteers. All the patients were clinically stable. The plasma unbound fraction of cyclosporine was estimat-ed using a modincation of the partitioning method of Garrett and colleagues. 5 Sufficient quantities of tritium-labelled cyclosporine and unlabelled cyclosporine were added to blood samples or red blood cell suspensions in order to achieve a tinal concentration of about 300 ng/mL. The red blood cell: plasma distribution ratio was estimated following incubation of blood samples for one hour at 37°C. Distribution equilibrium between blood cells and plasma is observed within 60 minutes. 6 The whole blood was centrifuged at 37°C in order to obtain plasma. Red blood cell to buffer partitioning of cyclosporine was estimated in blood cells. isolated from whole blood. washed three times with isotonic phosphate buffer. and resuspended in phosphate buffer to the initial hematocrit values. Red blood cell suspensions were incubated for 15 minutes at 37°C. Preliminary studies indicated that equilibrium between red blood cells and buffer is rapid and complete within ten minutes. 6 The concentrations of cyclosporine in whole blood. plasma. red blood cell suspension. and buffer were estimated by a liquid scintillation spectrometer using the channels ratio method for quench correction. Whole blood and red blood cell suspensions were counted after bleaching. according to standard techniques. 7 The unbound fraction of cyclosporine in plasma was calculated with the following equation
in which WB is the concentration of cycJosporine in whole blood. P is the concentration in plasma. RBC is the concentration of drug in red blood cells. B is the concentration of cyc1osporine in buffer. H is the hematocrit. and B/P is the unbound fraction of cyc1osporine in plasma. A t test for independent samples was used to compare different parameters obtained in transplant patients with that of healthy volunteers. A P value of less than or equal to .05 was considered to indicate signifIcant differences in the parameters estimated between different groups studied.
RESULTS
The blood:plasma ratio of cycJosporine in kidney and liver transplant patients was significantly [P < .05] lower than that in healthy volunteers (Table] . Liver and kidney transplant patients also had a lower hematocrit level as compared with healthy subjects IP < .05]. The RBC:buffer ratio. which is a measure of the affinity of red blood cells for cycJosporine. was very high in all of the subjects studied. The RBC:buffer ratio was highest for the liver transplant group and lowest for the renal transplant group. The mean ± standard deviation RBC:buffer ratio was 13. 8 This method also provides informalion on the erythrocyte uptake of cyclosporine. This method requires that the uptake of drugs into blood cells and the binding of drugs to plnsma protein be linear at the cnncentrntions used. Preliminary studies in our laboratory established that the red blood celluJltake of cyclosporine is Iinenr or concentration-independent lip to 800 ng/mL. In the present study. we used u concentration of only 300 ng/mL of cyclosporine. FlIJ'ther evidence in the Iilerature indicates Ihat the plasma protein binding of cyclospurine is also lineal' up to 5.000 ng/mL. 4 Estimations of RBC:lmffer and blood:plasma ratios and unbound fraclions by this method were very reproducible with a coefficient of variation of 5.3';;,·. 6.8%. and 7.8'/'" respectively (n = 3). As shown in the equation. the whole bloud:plasma ratio of a drug depends on the hematocrit level. RBC:buffer ratio (RUC uptake]. and B/P (unbound frnclion in plasma). The wide variation in the whule hlood:plasma ralio ohserved in our study is nllributable to the combined effects of differences in hematocrit levels, RBC uptake. and the unbound fractiun of cyclosporine in plasma between the different groups. Liver nnd renal transplant paticnts often have a low hematocrit concentrntion as compared with hea IIhy suojects. The fraction of the drug in hlood that resides in plasma is inversely corrclnteo with the hematocrit valueY Therefore. for a given whole blood concentration. more drug will be distributed in the plasma in these patients. Although cyclosporine was highly sequestered by RBC in all individuals. the uptake was lower in renal transplant patients. The rensons for the poor uptake of cyclosporine by RAC oblained from renaltransplanl patients is not c1eur at present. but may be relaled to qualitative und quantitutive differences in Ihe componenl responsible fur drug binding to erythrocytes.
Cyclosporine is primarily bound to lipoproteins in plasma. The large variation in the unbound fraction of cyclosporine in different patients may be u reflection of possible differences in Iho concentration of lipoproteins in the plasma of liwse suhjects. A high incidence of nn abnormnl plasma lipid profile hilS been reporled in renal transplant patients. 1fI · 11 Presently. there is no information available on 242 • J Ctin Pharmacol 1987;27:240-242 the lipoprotein profIles in liver transplant patients. lipoprotein pronles were not estimated in our study participants. The contribution of altered lipoprotein concentmtions to the variability observed in the unbound fraction of cyclosporine could not be evaluated in the present study.
A combination of altered lipoprotein pron Ie and variable hematocrit will result in marked differences in the unbound fraction of cyclosporine in the blood of transplant patients. Since cyclosporine is a low-to intermediate-clearance drug. its clearance is dependent on its unbound fmction in blood. Wide variations in the unbound fraction will therefore contribute to the wide variability in the clearance of cyclosporine observed in transplant patients. In addition. since hematocrit and lipoprotein concentrulions change with time after transplant. time-dependent changes in blood protein binding and clearance of cyclosporine would also be expected.
The results of our study indicate that there arc differences in blood protein binding of cyclosporine between transplant patients. This may contribute to the differences in the pharmacokinetics and pharmacodynamics of this immunosuppressant. Future studies should characterize the pharmacokinetics of unbound cyclosporine in bluod.
